Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | transmembrane protease, serine 4 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable glycogen phosphorylase GlgP | 0.0884 | 0 | 0.5 |
Mycobacterium ulcerans | glycogen phosphorylase GlgP | 0.0884 | 0 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.2044 | 1 | 1 |
Echinococcus granulosus | glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.2044 | 1 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.2044 | 1 | 1 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.2044 | 1 | 0.5 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Giardia lamblia | Glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.2044 | 1 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.2044 | 1 | 1 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.2044 | 1 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.2044 | 1 | 1 |
Chlamydia trachomatis | glycogen phosphorylase | 0.2044 | 1 | 0.5 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.2044 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = 7 % | Inhibition of Wnt/beta-catenin in human HCT116 cells assessed as remaining cytosolic beta-catenin level at 2 uM after 18 hrs by Western blot analysis relative to control | ChEMBL. | 26272032 |
IC50 (binding) | = 0.29 uM | Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs | ChEMBL. | 26272032 |
IC50 (ADMET) | = 0.36 uM | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay | ChEMBL. | 24953953 |
IC50 (ADMET) | = 5.3 uM | Cytostatic activity against human MONO-MAC-6 cells assessed as cell viability after 16 hrs by MTT assay | ChEMBL. | 26210507 |
IC50 (binding) | = 16 uM | Inhibition of N-terminal His6-tagged recombinant TMPRSS4 (unknown origin) fused with enterokinase cleavage sequence DYKDDDGDYKDDDDK expressed in Escherichia coli BL21 (DE3) using Z-Phe-Arg-7-amido-4-methylcoumarin hydrochloride as substrate by fluorometric analysis | ChEMBL. | 23414802 |
MIC (functional) | = 1 uM | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 14 days | ChEMBL. | 24953953 |
MIC (functional) | = 1.6 uM | Antimycobacterial activity against multidrug-resistance Mycobacterium tuberculosis A8 after 28 days by serial dilution method | ChEMBL. | 26210507 |
MIC (functional) | = 1.6 uM | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC27294 assessed as complete cessation of growth | ChEMBL. | 23211970 |
MIC (functional) | = 2 uM | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days by microdilution method | ChEMBL. | 25593095 |
MIC (functional) | = 2 uM | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days by microdilution method | ChEMBL. | 25593095 |
MIC (functional) | = 2 uM | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 21 days | ChEMBL. | 24953953 |
MIC (functional) | = 2 umol/L | Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 14 days by micromethod | ChEMBL. | 22907036 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 24953953 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.